Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Dapatifagene Navolactibac · AG013

Microbiome therapy · developed by Oragenics

Phase 2 Most advanced trial (none active)
OGEN Developer
1 Registered trials

What is Dapatifagene Navolactibac?

Dapatifagene navolactibac is an oral rinse containing Lactococcus lactis bacteria genetically modified to secrete human trefoil factor 1 (hTFF1), a peptide normally secreted by mucous epithelia that helps protect and heal mucosal tissue. It is studied in oral mucositis, damage to the mouth lining caused by cancer therapies such as chemotherapy and radiation.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
AG013
Drug type
Microbiome therapy
Pathways
mucosal protection, mucosal healing
Therapy area
Gastroenterology, Oncology
Developer
Oragenics, Inc. (OGEN)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
8FFT787E61

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT03234465 Phase 2 Oral Mucositis Terminated OGEN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Oral Mucositis

More from Oragenics

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the OGEN page.

Follow OGEN, the company behind Dapatifagene Navolactibac

See OGEN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

OGEN catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.